IOLC 2025: Turning Oncology Leadership Into Real-World Impact

Earlier this month, global oncology leaders gathered in Lisbon for the 9th International Oncology Leadership Conference (IOLC 2025) to discuss a central question: How do we transform clinical needs into meaningful innovation?

The sessions covered a broad spectrum of challenges – expanding worldwide access to cancer care, accelerating cell therapy, integrating AI into workflows, and translating emerging technologies into real clinical environments. The key takeaway was clear: leadership in oncology is not defined by strategy alone. It is defined by execution, collaboration, and the ability to turn expertise into tangible results.

Together with our partner Michael Teicher from EHMET Health and our CEO Guido Kübler, we joined the conversations to listen, exchange insights, and contribute our perspective. At gKteso, we believe that bridging administrators, clinicians, and engineers is essential to driving progress.

From clinical access to OEM-ready radiotherapy technologies, we are proud to be part of the discussions shaping the future of cancer care.